This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
B A C K G R O U N D
Hypertension (blood pressure above a recommended value) is a common clinical condition with a well-established causal role in cardiovascular disease (Lewington 2002) . Hypertension is particularly prevalent in older age; more than half of the population over the age of 50 years, and approximately 80% of the population older than 80 years have hypertension (Chow 2013; Cohen 2011) . The protective effect of antihypertensive treatment against cardiovascular events and premature mortality is well established (Law 2009; Musini 2009 ). The evidence to support treatment of hypertension in healthy older adults is robust (Beckett 2012) . Evidence for benefit of antihypertensive therapy in frail older adults with comorbidities and geriatric syndromes including cognitive and functional decline is limited, and some data suggest potential for harm, with studies describing association between antihypertensive therapy and higher mortality (Benetos 2015) , and serious injuries arising from falls (Tinetti 2014).
The evidence for antihypertensive therapy in those with cognitive impairment or dementia, and the impact of this treatment on cognition is uncertain, with conflicting results in published data and no meta-analysis possible due to heterogeneity (Beishon 2014) . Data have variously shown a protective, harmful or neutral effect of antihypertensives on cognition. A study with almost 5000 older adults, suggested no detrimental effect of antihypertensive treatment on cognitive function in people with existing cognitive problems . Two other large studies did not show a reduction of incident dementia in patients treated with antihypertensive medications (Di Bari 2001; Peters 2008) . However, other work has suggested a protective effect of antihypertensive treatment on vascular induced dementia (Tzourio 2003) , while another study reported potential for antihypertensive medication to accelerate cognitive decline (Alrawi 2013) .
These seemingly conflicting trial data may be explained by the complex relationship between blood pressure and cognition over the life course. Hypertension in middle-age is a risk factor for incident dementia, driven at least in part by cerebrovascular disease (Norton 2014). However, the association between blood pressure and dementia at an older age is inverse (Kennelly 2009; Qiu 2009) . Several years before dementia onset, a decrease in blood pressure can be seen (Skoog 1996) , and low blood pressure is associated with cognitive decline in the years after diagnosis (Nilsson 2007), although the direction of causality is unknown. Several mechanisms have been proposed to underlie this decrease in blood pressure in the years before the diagnosis of dementia, including autonomic dysregulation as symptom of neurodegeneration (den Abeelen 2014). The arteriosclerotic and age-related changes to cerebral blood flow autoregulation in older people could also result in cerebral hypoperfusion, potentially influencing cognitive functioning (Qiu 2009). Thus, the evidence base for cognitive benefits of hypertension treatment in midlife is compelling, but the evidence for cognitive effects of hypertension treatment in older age is less clear. The Cochrane systematic review on hypertension treatment in the elderly showed that adherence to treatment is limited and a considerable proportion of older patients discontinue treatment, due to adverse effects, in particular when the level of prescribed treatment increased (Musini 2009) . Taking all this into account, there is a concern that antihypertensive medication may have potential for harm in those with cognitive impairment/dementia and it may negatively influence cognitive functioning. There has been associated debate regarding the benefit of withdrawing antihypertensive therapy in older adults, since the risk-benefit ratio of treatment might be different at differing ages and with different classes of antihypertensive medications (Shah 2009 ).
It would be interesting for policymakers if withdrawal of hypertensive medications has a positive effect on cognitive functioning, since this might possibly lead to a decrease in dementia incidence and thus major health cost savings. Reducing medication use will also contribute to less healthcare expenditures.
The purpose of this systematic review is to summarise all available evidence on cognitive effects of withdrawal of antihypertensive medications and associated benefits and harms in adults (including healthy adults and those with prevalent cognitive decline).
Description of the condition
We will focus on the implications of antihypertensive medication on cognitive functioning, including cognitive decline and dementia. Cognitive decline is often accompanied by deterioration in emotional control, social behaviour, or motivation. The number of people living with cognitive impairment not classified as dementia is probably even higher, but no exact data on this exist. The term 'dementia' refers to a group of diseases which shares a syndrome that is typically chronic and progressive in nature. The dementia syndrome involves disturbances of multiple higher cortical functions, such as memory, thinking, orientation, perception and behaviour, which are severe enough to affect the ability to perform everyday activities. The number of people living with dementia is increasing due to the ageing world population. Currently, worldwide 47.5 million people are estimated to be affected. This number will double within the next 20 years, resulting in high costs and considerable burden to individuals and societies (WHO 2015) .
Description of the intervention
In this review we will identify and appraise controlled clinical trials which evaluate the cognitive consequences of withdrawal of antihypertensive treatment in adults.
How the intervention might work
There are plausible theoretical reasons why withdrawal of antihypertensive therapy may have a beneficial effect on cognition, mostly relating to improving cerebral perfusion. Equally, withdrawal of antihypertensive therapy may accelerate cognitive decline through incident stroke or progression of small vessel disease.
Interventions to completely withdraw at least one antihypertensive medication in patients with and without cognitive problems may also reduce adverse effects and improve quality of life for the patient and carer. However, they may also cause withdrawal symptoms like "rebound" tachycardia with withdrawal of beta-blocker, headache, agitation and nausea (Karachalios 2005). We will therefore examine trials which evaluate effects of antihypertensive withdrawal, contributing to the evidence base in this area.
Why it is important to do this review
Contemporary guidelines for blood pressure management in older adults focus on indications for treatment and choice of treatment. There is ground to suspect that withdrawal of antihyperten-Library Trusted evidence. Informed decisions. Better health.
Cochrane Database of Systematic Reviews sive medication in certain older adult populations may have beneficial effects on cognition and/or rate of dementia. A cost saving intervention (drug withdrawal) that impacts on cognition would have important individual and public health implications. A synthesis of all relevant data will move us closer to adopting evidence based interventions, or will identify the evidence gaps that require further original research. In general, studies that address the effect of withdrawal of drugs in (frail) older populations are highly relevant to prevent unnecessary and potentially harmful treatments.
O B J E C T I V E S
The objective is to assess the effects of complete withdrawal of at least one antihypertensive medication on cognitive function in healthy and cognitive impaired adults.
M E T H O D S Criteria for considering studies for this review

Types of studies
We will select studies if they meet the following criteria: randomised controlled trials (RCTs) comparing withdrawal of antihypertensive medications with continuation of the medications. We will also include controlled clinical trials (CCTs) that meet other inclusion criteria. An outcome measure assessing cognitive function or dementia diagnosis must be clearly defined.
Types of participants
Participants must be aged 18 years and over. Participants must have been taking the antihypertensive medications for a minimum of one month irrespective of indication.
Participants may reside in any healthcare setting (including acute hospitals, nursing and residential homes and the community). We will include healthy participants and participants with all grades of severity of dementia or cognitive impairment.
Types of interventions
Withdrawal of any medication with blood pressure lowering effects (see list of relevant medications included in Appendix 1) with no restriction to duration of follow-up.
Types of outcome measures
Primary outcomes
• Cognitive impairment or rates of incident dementia in healthy and cognitive impaired adults • Cognition in the short-term in adults with or without established cognitive impairment. 
Secondary outcomes
• Effects on systolic and diastolic blood pressure.
• Adherence to withdrawal of the antihypertensive medications. We will define adherence to withdrawal as patients remaining o medication for the duration of the study or at least six months, whichever is longer. • Rates of serious adverse events across the included studies.
Including mortality, cardiovascular events, early (within first 8 weeks) and late (post-six months) adverse effects (e.g. falls and hospitalisation).
Search methods for identification of studies
We will use the electronic databases listed below to search for relevant studies regardless of language, personnel, research setting or date of publication.
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois) -the Cochrane Dementia and Cognitive Improvement Group's (CDCIG) specialised register.
ALOIS is maintained by the Trials Search Co-ordinator for the CD-CIG, and contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy older adult populations. The studies are identified through: To view a list of all sources searched for ALOIS see AboutALOIS on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic databases, used for the retrieval of reports of dementia, cognitive improvement and cognitive enhancement trials, can be viewed in the 'methods used in reviews' section within the editorial information about the Cochrane Dementia and Cognitive Improvement Group.
We will run additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, Web of Science core collection, ClinicalTrials.gov and the WHO Portal/ICTRP to ensure that the search is as comprehensive and as up-to-date as possible. The search strategy that we will use to retrieve reports of trials from MEDLINE (via the Ovid SP platform) can be seen in Appendix 2.
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Searching other resources
In case of incomplete reports, we will conduct further searches for connected papers, or we will contact authors to retrieve missing information.
We will handsearch the reference lists of all of the relevant articles that we retrieve and search for non-MEDLINE listed journals. We will also search the Science Citation Index for articles citing key references. We will contact authors of relevant papers and relevant organisations to identify additional studies, including unpublished and ongoing studies. Finally, we will revise key original database search strategies based on the yield of the above searches and update for subsequent reviews.
Data collection and analysis
Selection of studies
Phase 1: Two review authors (SJ and JH) will perform searches and screening of identified studies independently. We will independently examine titles and abstracts of citations obtained from the searches and discard obviously irrelevant articles. At this stage, we will be overly inclusive; we will retrieve for further assessment of any article that suggests a relevant trial.
Phase 2: From the potentially relevant articles in Phase I, two review authors (SJ and JH) will independently select trials (based on the full-text format) for inclusion. We will resolve disagreement on study inclusion by consensus or third party adjudication. We will detail the study selection process in a PRISMA flow diagram (Moher 2009).
Data extraction and management
Two independent review authors (SJ and JH) will perform data extraction using a prespecified data extraction form and enter the data into Review Manager software (RevMan 2014).
Assessment of risk of bias in included studies
At least two independent review authors (SJ and JH) will assess the internal validity of each included study. Where relevant details are unclear, we will ask for clarification and we will discuss discrepancies with a third reviewer (ER), if necessary. We will use the Cochrane 'Risk of bias' tool for assessment and we will use seven standard criteria: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; other risk of bias (Higgins 2011). We will assess every study for each of the seven criteria and report the information in a 'Risk of bias' table.
We will restrict the primary analysis to studies at low or unclear risk of bias. We will perform sensitivity analyses to determine how conclusions might be affected if studies at high risk of bias are added to the analysis.
Measures of treatment e ect
In the first instance we will present a narrative description of studies and results; if data allow we will perform a meta-analysis to describe summary effects.
The meta-analysis will require the combination of data from trials that may not use the same rating scale or test to assess an outcome.
The measure of the withdrawal of treatment difference for any outcome will be the weighted mean difference when the pooled trials use the same assessment instrument, and the standardised mean difference when different assessment instruments are used. For binary outcomes we will use the odds ratio (OR) to measure treatment effect and calculate a weighted estimate of the typical treatment effect across trials.
Unit of analysis issues
We will consider for each study whether groups of individuals were randomised together to the same intervention (i.e. cluster-randomised trials), whether individuals underwent more than one intervention (e.g. in a cross-over trial, or simultaneous treatment of multiple sites on each individual) or whether there are multiple observations for the same outcome (e.g. repeated measurements, recurring events).
Dealing with missing data
We will contact authors of studies if there are missing data crucial for the interpretation or the use in quantitative meta-analysis and we will report this. We will make a qualitative judgement as to whether to exclude studies if the impact of missing data is too large.
Assessment of heterogeneity
We will only perform a meta-analysis when studies are sufficiently homogeneous in terms of participants, interventions and outcomes. Statistical heterogeneity will be considered by using the I 2 test (Higgins 2011). We will consider heterogeneity of 30% to 60% as moderate, 50% to 90% as substantial and 75% to 100% as considerable. We will make a decision on the appropriateness of metaanalysis based on statistical and clinical heterogeneity.
Assessment of reporting biases
We will search for non-published as well as published studies in databases and trial registries, to avoid publication bias. To avoid language bias, we will not employ language restrictions for included studies. Where there are multiple publications from one study, we will only include the primary publication to address duplicate publication bias. To investigate the likelihood of overt publication bias, we will enter data from all identified trials into a funnel plot.
Data synthesis
We will decide on suitability of meta-analysis for each outcome by a qualitative assessment (including statistical and clinical heterogeneity) of the included studies.
We will conduct data synthesis and analyses using Review Manager software (RevMan 2014). We will use risk ratios (RRs) and a random-effects model to combine outcomes across trials for a metaanalysis. The weighting factor for each study is the inverse of the within-study variance plus a between-study variance component. If it is not possible to combine outcome data due to differences in the reporting or substantive heterogeneity, we will report a narrative summary.
Study duration of trials may vary. If the range of study duration is considered too large to pool all trials into one meta-analysis, we will divide the data into smaller time periods and conduct a separate meta-analysis for each period. Some trials may contribute da- Cochrane Database of Systematic Reviews ta to more than one time period if multiple assessments have been made.
Subgroup analysis and investigation of heterogeneity
If around 10 or more trials are identified that contribute to the analyses of primary outcomes, we aim to perform stratified analyses of the primary effectiveness outcome, according to the following trial characteristics: presence versus absence of dementia or cognitive impairment at baseline, age, type of antihypertensive treatment (thiazide diuretics, ACE inhibitors, etc.).
Data presentation -'Summary of findings' tables
We will use the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach to assess the quality of the supporting evidence behind each estimate of treatment effect (Schunemann 2011a; Schunemann 2011b) . We will present key findings of the review including a summary of the amount of data, the magnitude of the effect size and the overall quality of the evidence, in a 'Summary of findings' table, created using GRADEproGDT software (GRADEproGDT 2015). We have preselect-ed the following outcomes: cognitive impairment (1. incident dementia (clinical diagnosis) and 2. change in a validated cognitive test score); change in systolic and diastolic blood pressure; mortality; cardiovascular events; falls; hospitalisation and re-commencement of antihypertensive medications.
Sensitivity analysis
We will perform a sensitivity analysis for pooled results based on methodological quality if possible. Many issues suitable for a sensitivity analysis can only be identified during the review process when the individual peculiarities of studies under investigation are identified. We will perform sensitivity analyses without possibly included CCTs to look at the effect of these studies and to avoid risk of bias.
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